Reuters logo
5 个月前
BRIEF-Benitec Biopharma says key pre-clinical data on muscular dystrophy published in nature communications
2017年4月4日 / 下午12点37分 / 5 个月前

BRIEF-Benitec Biopharma says key pre-clinical data on muscular dystrophy published in nature communications

April 4 (Reuters) - Benitec Biopharma Ltd:

* Benitec Biopharma Ltd - key pre-clinical data on oculopharyngeal muscular dystrophy (opmd) published in nature communications

* Benitec Biopharma Ltd - data from studies show ddrnai approach to 'silence and replace' mutant pabpn1 protein, results in correction of muscular dystrophy

* Benitec Biopharma - data from studies show ddrnai approach to 'silence and replace' mutant pabpn1 protein, results in correction of key clinical features of opmd

* Benitec Biopharma Ltd - bb-301 is currently in preclinical development and benitec plans to initiate ind-enabling studies later this year Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below